prestige biopharm hd201

Bio & Pharma SK Biopharm submits NDA of epilepsy drug to China

South Korea's SK Biopharmaceuticals Co. said on Tuesday it submitted the new drug application (NDA) for its flagship epilepsy drug Cenobamate to Chi...

Automobiles Hyundai Motor releases 2025 Santa Fe

Hyundai Motor Co. said on Tuesday that it released the 2025 Santa Fe, a model year change of its flagship midsize sports utility vehicle (SUV) The A...

Bio & Pharma SK Biopharm mulls acquiring firms, drug sales rights in US

SAN DIEGO, California -- South Korea’s SK Biopharmaceuticals Co. is considering acquiring firms in the US, or the sales rights to some of thei...

Bio & Pharma Korea’s Celltrion, SK Biopharmaceuticals benefit from direct US sales

Celltrion Inc. and SK Biopharmaceuticals Co. are witnessing improving sales revenue and profitability by selling their products through their own ma...

Bio & Pharma SK Biopharm targets $311 mn for Cenobamate US sales

South Korea's SK Biopharmaceuticals targeted 416 billion won ($311 million) for its epilepsy treatment Cenobamate in the US market this year. SK Bi...

Bio & Pharma SK Biopharm, Dong-A ST sign licensing deal of Cenobamate

South Korea's SK Biopharmaceuticals Co. announced on Thursday that it has signed a contract with Dong-A ST to transfer the rights to commercialize t...

Bio & Pharma SK Biopharm gears up to boost epilepsy drug sales in Europe

SK Biopharmaceuticals Co. is gearing up to explore the European market for its flagship epilepsy drug Cenobamate, while looking for new mergers and ...

Bio & Pharma Prestige Biologics partners with Indian company for CDMO

Prestige Biologics Co., a South Korean biopharmaceutical contract development and manufacturing organization (CDMO) company, is expanding its CDMO b...

Bio & Pharma SK Biopharm to export epilepsy drug tech to Middle Eastern firm

South Korea's SK Biopharmaceuticals announced on Friday a strategic tie-up with Hikma MENA FZE, marking the introduction of its new epilepsy medicat...

Bio & Pharma SK Biopharm eyes Asia's No.1 spot in radioactive drug market

South Korea’s SK Biopharmaceuticals Co. is aiming to triple its enterprise value to $15 billion by 2026 with the goal of rising to the top run...

Bio & Pharma Prestige Biopharma participates in US gov’t Cancer Moonshot

Prestige Biopharma, a Singapore-based biopharmaceutical company with operations in South Korea and the US, announced on Tuesday that it will partici...

Bio & Pharma SK Biopharm’s Cenobamate gets nod in Canada, to boost US sales

South Korea’s SK Biopharmaceuticals Co. has obtained the sales approval for its antiepileptic treatment Cenobamate in Canada, paving the way f...

Mergers & Acquisitions Celltrion drops bid to acquire Baxter’s biopharm unit

Celltrion Inc. announced on Tuesday it has decided not to pursue the acquisition of the biopharmaceutical unit of U.S. medical device maker Baxter I...

Bio & Pharma Prestige Bio's pancreatic cancer treatment gets US FDA fast-track designation

Prestige Biopharma, a biopharmaceutical company in South Korea, announced on Thursday that their pancreatic cancer antibody drug, PBP1510 (Ulenistam...

Bio & Pharma S.Korea's Prestige Biologics attracts $59 mn overseas investment

Prestige Biologics Co., a South Korean biopharmaceutical contract development and manufacturing organization (CDMO) company, announced on Tuesday th...

Bio & Pharma SK Biopharm holds sales meeting for marketing Cenobamate in US

On Wednesday, SK Biopharmaceuticals Co. announced that its US subsidiary, SK Life Sciences Inc., held a "National Sales Meeting" in San Diego. The p...

Bio & Pharma Prestige Bio's Herceptin biosimilar proves equivalence in clinical trials

Prestige Biopharma, a South Korean biopharmaceutical developer, said on Tuesday that the final analysis of phase 3 clinical trial on the anti-cancer...

Bio & Pharma Prestige Biopharma submits clinical trial plan in Australia

Prestige Biopharma, a Singapore-based biopharmaceutical company with operations in South Korea and the US,  has applied to the Australian clini...

Bio & Pharma Prestige Biopharma attains patent for solid cancer treatment antibody

Prestige Biopharma Korea said on Tuesday that it has obtained a domestic patent for the CTHRC1 neutralizing antibody of the drug candidate PBP1710. ...

Bio & Pharma SK Biopharm begins clinical trials of wearable device for detecting epilepsy

SK Group's new drug development subsidiary SK Biopharmaceuticals Co. will begin clinical trials for a wearable device that can detect and predict ep...

Bio & Pharma SK Biopharmaceuticals launches epilepsy drug in France

South Korean SK Biopharmaceuticals Co. said on Friday that its treatment of epilepsy "Cenobamate" has been approved for sale in France.The company l...

Bio & Pharma SK Biopharma's epilepsy treatment posts impressive growth in US

South Korean SK Biopharmaceuticals' epilepsy treatment Cenobamate has seen rapid growth on the US market.The company on Thursday said the medic...

Bio & Pharma SK Biopharmaceuticals signs epilepsy drug deal with Brazil’s Eurofarma

South Korea’s SK Biopharmaceuticals Co. has signed a deal to license out its technology for Cenobamate, an antiepileptic drug, to Brazil&rsquo...

Pharamaceuticals SK Biopharm releases epilepsy treatment in UK

South Korean SK Biopharmaceuticals Co. launched its epilepsy treatment Cenobamate in the UK, rapidly expanding the company’s presence in Europ...

E-commerce Yanolja likely to buy $250 mn stake in Interpark spin-off

South Korea's top travel and accommodation platform Yanolja Inc., backed by SoftBank, was on Thursday named as the preferred buyer of a majority sta...

Pharmaceuticals SK Biopharm aims to make it to global top 10 healthcare firms by 2030

South Korea’s SK Biopharmaceuticals Co. said on Friday it aspires to become one of the world’s top 10 healthcare companies by 2030 with ...

Block deal SK Holdings raises $1 bn from block sale of SK Biopharm shares

South Korea's SK Holdings Co. has offloaded an 11% stake in SK Biopharmaceuticals Co. in a block trade for 1.1 trillion won ($1 billion) as part of ...

Markets S. Korean stock market posts record-high market cap; SK biopharm added to MSCI

South Korea's benchmark Kospi reached a two-year high closing at 2485.87 points on Nov. 11, posting an eight-session winning streak driven by imminent...

IPO BTS’ label, SK Biopharm gearing up for billion-dollar IPOs in 2020

Big Hit Entertainment Co. Ltd., the label behind the K-pop boy band BTS and SK Biopharmaceuticals Co. Ltd. are moving ahead with their planned initial...